Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
Published: April 22, 2022
Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
Oren Auster, MSc1; Uriah Finkel, MA1; Noa Dagan, MD, PhD, MPH1,2,3,4; et al
BACK